PCVX

Vaxcyte's stock price has been significantly impacted by several key events in the past six months. On October 5, 2026, Vaxcyte announced positive topline data from its pivotal adult Phase 3 trial (OPUS-1) for VAX-31, which met all primary immunogenicity endpoints, demonstrating non-inferiority against comparator vaccines and superiority for unique serotypes, leading to a substantial surge in PCVX shares. On October 9, 2026, the company completed public offerings of common stock, pre-funded warrants, and convertible senior notes, raising approximately $1.15 billion. In May 2026, Vaxcyte announced the completion of enrollment for its OPUS-1, OPUS-2, and OPUS-3 adult Phase 3 trials for VAX-31. In January 2026, Vaxcyte established a dedicated presence in North Carolina to focus on chemistry, manufacturing, and controls (CMC) activities and to expand U.S.-based fill-finish manufacturing capacity for its PCV candidates.